Brief: Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology For Oligomer-Selective Antibodies
02/12/2025 14:13
Dec 2 (Reuters) - Acumen Pharmaceuticals Inc ABOS.O: ACUMEN PHARMACEUTICALS HIGHLIGHTS ENHANCED BRAIN DELIVERY™ TECHNOLOGY FOR OLIGOMER-SELECTIVE ANTIBODIES AND RECRUITMENT STRATEGIES FOR PHASE 2 ALTITUDE-AD CLINICAL TRIAL AT 18TH ANNUAL CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE Source text: ID:nGNX2RQvlL Further company coverage: ABOS.O ((Reuters.Briefs@thomsonreuters.com;))